• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

日本非重型血友病 A 患者凝血检测结果差异。

Coagulation assay discrepancies in Japanese patients with non-severe hemophilia A.

机构信息

Department of Laboratory Medicine, Tokyo Medical University, 6-7-1 Nishishinjuku, Shinjuku-ku, Tokyo, 160-0023, Japan.

Scientific Research, Scientific Affairs, Sysmex Corporation, Kobe, Japan.

出版信息

Int J Hematol. 2022 Feb;115(2):173-187. doi: 10.1007/s12185-021-03256-x. Epub 2021 Nov 9.

DOI:10.1007/s12185-021-03256-x
PMID:34751920
Abstract

Patients with non-severe hemophilia A often show discrepancies in factor VIII (FVIII) activity. However, information on variant-specific coagulation assay characteristics in Japanese patients is limited. Pathogenic variants were classified into three groups, thrombin-cleavage site (TC), A1-A2-A3 interface (IF), and non-discrepant, with reference to previous studies. Cutoff values for the one-stage assay (OSA)/chromogenic substrate assay (CSA) ratio, which is suitable for distinguishing discrepancies, were determined for all five aPTT reagents. TGA and CWA parameters and bleeding scores were compared between groups. Two of the 39 patients with non-severe hemophilia A (5%) were classified as TC, 10 (26%) as IF, and 27 (69%) as non-discrepant. The OSA/CSA cutoff values between the groups varied widely by aPTT reagent and tended to be relatively low compared to previous studies. As an indicator of bleeding tendency, TGA had a low correlation coefficient for the IF variant, but this was not significant and was comparable to FVIII activity and CWA. Moreover, various parameters and bleeding tendency differed among patients with the same variants. Thus, our findings suggest that it is difficult to adequately assess the bleeding tendency of individual patients, even with the various assessments currently available.

摘要

非重型血友病 A 患者的因子 VIII (FVIII) 活性常存在差异。然而,关于日本患者变异特异性凝血检测特征的信息有限。根据以往的研究,将致病性变异分为三个组:凝血酶裂解位点 (TC)、A1-A2-A3 界面 (IF) 和无差异。为所有五种活化部分凝血活酶时间 (aPTT) 试剂确定了适合区分差异的一期法 (OSA)/发色底物法 (CSA) 比值的截断值。比较了各组之间的 TGA 和 CWA 参数和出血评分。39 名非重型血友病 A 患者中有 2 名 (5%) 被归类为 TC,10 名 (26%) 为 IF,27 名 (69%) 为无差异。各组之间的 OSA/CSA 截断值因 aPTT 试剂而异,与以往的研究相比,这些截断值往往相对较低。作为出血倾向的指标,IF 变异的 TGA 相关系数较低,但无统计学意义,与 FVIII 活性和 CWA 相当。此外,具有相同变异的患者的各种参数和出血倾向存在差异。因此,我们的研究结果表明,即使目前有各种评估方法,也很难充分评估个体患者的出血倾向。

相似文献

1
Coagulation assay discrepancies in Japanese patients with non-severe hemophilia A.日本非重型血友病 A 患者凝血检测结果差异。
Int J Hematol. 2022 Feb;115(2):173-187. doi: 10.1007/s12185-021-03256-x. Epub 2021 Nov 9.
2
Discrepancy between the results of one-stage and chromogenic factor VIII: C assays in patients with mild/moderate hemophilia A.一期法和显色因子 VIII:C 检测在轻/中度血友病 A 患者中的结果差异。
Blood Coagul Fibrinolysis. 2020 Dec;31(8):530-535. doi: 10.1097/MBC.0000000000000959.
3
Impact of variation in reagent combinations for one-stage clotting assay on assay discrepancy in nonsevere haemophilia A.一步法凝血检测中试剂组合变化对非重型血友病 A 检测差异的影响。
Int J Lab Hematol. 2021 Feb;43(1):131-138. doi: 10.1111/ijlh.13335. Epub 2020 Sep 11.
4
Genetic analysis of non-severe hemophilia A phenotype with A discrepancy between one-stage and chromogenic factor VIII activity assays.一期法与发色底物法检测Ⅷ因子活性结果不一致的非重型A型血友病表型的基因分析
Transfus Apher Sci. 2021 Oct;60(5):103194. doi: 10.1016/j.transci.2021.103194. Epub 2021 Jul 7.
5
Haemophilia A mutations in patients with non-severe phenotype associated with a discrepancy between one-stage and chromogenic factor VIII activity assays.非严重表型患者中A型血友病突变与一期法和发色底物法检测因子VIII活性结果不一致相关。
Thromb Haemost. 2014 May 5;111(5):851-61. doi: 10.1160/TH13-08-0690. Epub 2014 Jan 23.
6
Diagnostic testing for mild hemophilia a in patients with discrepant one-stage, two-stage, and chromogenic factor VIII:C assays.在一期、二期和显色因子 VIII:C 测定结果不一致的轻度血友病 A 患者中进行诊断性检测。
Semin Thromb Hemost. 2013 Apr;39(3):272-82. doi: 10.1055/s-0033-1334863. Epub 2013 Mar 4.
7
In silico and in vitro evaluation of the impact of mutations in non-severe haemophilia A patients on assay discrepancies.非重型血友病 A 患者突变对检测差异影响的计算机模拟和体外评估。
Ann Hematol. 2019 Aug;98(8):1855-1865. doi: 10.1007/s00277-019-03691-1. Epub 2019 Apr 17.
8
Overall hemostasis potential and aPTT-clot waveform analysis as powerful laboratory diagnostic tools for identification of hemophilia A patients with unexpected bleeding phenotype.总体止血潜能和 aPTT-凝块波形分析是血友病 A 患者伴意外出血表型鉴定的强有力实验室诊断工具。
Int J Lab Hematol. 2021 Apr;43(2):273-280. doi: 10.1111/ijlh.13347. Epub 2020 Sep 23.
9
Clinical utility of activated partial thromboplastin time clot waveform analysis and thrombin generation test in the evaluation of bleeding phenotype in Hemophilia A.活化部分凝血活酶时间(APTT)凝块波形分析和凝血酶生成试验在评估血友病 A 出血表型中的临床应用。
Indian J Pathol Microbiol. 2021 Jan-Mar;64(1):117-122. doi: 10.4103/IJPM.IJPM_336_19.
10
Specific and global coagulation assays in the diagnosis of discrepant mild hemophilia A.特定和整体凝血检测在不一致性轻型血友病 A 诊断中的应用。
Haematologica. 2013 Dec;98(12):1980-7. doi: 10.3324/haematol.2013.088088. Epub 2013 Jun 28.

引用本文的文献

1
A graph-based machine learning framework identifies critical properties of FVIII that lead to hemophilia A.一种基于图的机器学习框架识别出导致甲型血友病的凝血因子VIII的关键特性。
Front Bioinform. 2023 May 10;3:1152039. doi: 10.3389/fbinf.2023.1152039. eCollection 2023.
2
Prolonged α-thrombin-related activation and delayed active protein C-associated degradation confer mild phenotype in a patient with severe hemophilia A with F8 p.H118R.患者存在 F8 p.H118R 突变的重型血友病 A,其 α-凝血酶相关激活时间延长,且 APC 相关降解延迟,导致表型较轻。
Int J Hematol. 2022 Oct;116(4):489-499. doi: 10.1007/s12185-022-03381-1. Epub 2022 May 19.

本文引用的文献

1
Thrombin generation in haemophilia A patients with mutations causing factor VIII assay discrepancy.血友病 A 患者中导致因子 VIII 检测结果差异的突变与凝血酶生成。
Haemophilia. 2010 Jul 1;16(4):671-4. doi: 10.1111/j.1365-2516.2009.02190.x. Epub 2010 Feb 9.